|
Completed
|
NCT06106932 -
GnRH-a on Angiogenesis of Endometriosis
|
N/A |
|
Completed
|
NCT04974983 -
Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
|
|
|
Recruiting
|
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 |
|
Recruiting
|
NCT04145505 -
Micrometastases and Angiogenesis in Colon Cancer. Prognostic Value of VEGF.
|
|
|
Active, not recruiting
|
NCT02396888 -
Effects of Local Insulin on Wound Angiogenesis
|
Phase 3 |
|
Completed
|
NCT03705247 -
The Role of Bleeding at Implant Placement
|
|
|
Recruiting
|
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 |
|
Completed
|
NCT04609332 -
Endothelial Damage and Angiogenesis Biomarkers During COVID-19
|
|
|
Completed
|
NCT03162588 -
Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT04772001 -
Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer
|
N/A |
|
Not yet recruiting
|
NCT04807166 -
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
|
Phase 2 |
|
Completed
|
NCT04310280 -
Effects of Local Insulin on Varicose Ulcers for Wound Healing
|
Phase 3 |
|
Completed
|
NCT04670107 -
The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy
|
Phase 1/Phase 2 |
|
Completed
|
NCT00727948 -
The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy
|
Early Phase 1 |
|
Completed
|
NCT02603406 -
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits
|
Phase 2 |
|
Recruiting
|
NCT03991871 -
HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study
|
N/A |
|
Completed
|
NCT00744536 -
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS
|
Phase 2 |
|
Completed
|
NCT00728598 -
Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
|
N/A |
|
Active, not recruiting
|
NCT04851054 -
Postoperative VEGF and Recurrence After Colon Cancer Surgery
|
|
|
Not yet recruiting
|
NCT02865304 -
The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients
|
Phase 3 |